Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice

ABSTRACTPurposeTo study the influence of protein aggregation on the immunogenicity of recombinant human interferon beta (rhIFNβ) in wild-type mice and transgenic, immune-tolerant mice, and to evaluate the induction of immunological memory.MethodsRhIFNβ-1b and three rhIFNβ-1a preparations with different aggregate levels were injected intraperitoneally in mice 15× during 3 weeks, and the mice were rechallenged with rhIFNβ-1a. The formation of binding (BABs) and neutralizing antibodies (NABs) was monitored.ResultsBulk rhIFNβ-1a contained large, mainly non-covalent aggregates and stressed rhIFNβ-1a mainly covalent, homogeneous (ca. 100 nm) aggregates. Reformulated rhIFNβ-1a was essentially aggregate-free. All products induced BABs and NABs in wild-type mice. Immunogenicity in the transgenic mice was product dependent. RhIFNβ-1b showed the highest and reformulated rhIFNβ-1a the lowest immunogenicity. In contrast with wild-type mice, transgenic mice did not show NABs, nor did they respond to the rechallenge.ConclusionsThe immunogenicity of the products in transgenic mice, unlike in wild-type mice, varied. In the transgenic mice, neither NABs nor immunological memory developed. The immunogenicity of rhIFNβ in a model reflecting the human immune system depends on the presence and the characteristics of aggregates.

[1]  S Porter,et al.  Human immune response to recombinant human proteins. , 2001, Journal of pharmaceutical sciences.

[2]  P. Gallo,et al.  Interferon-beta (IFN-β) antibodies in interferon-β1a-and interferon-β1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo , 2001 .

[3]  A. Bertolotto,et al.  Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments , 2005, Neurological Sciences.

[4]  S. Kimura,et al.  Stability of human interferon-beta 1: oligomeric human interferon-beta 1 is inactive but is reactivated by monomerization. , 1989, Biochimica et biophysica acta.

[5]  J. Ralston,et al.  Solution Behavior of IFN-β-1a: An Empirical Phase Diagram Based Approach , 2005 .

[6]  John M. Walker,et al.  The Protein Protocols Handbook , 2009, Springer Protocols Handbooks.

[7]  J. Peter-Katalinic,et al.  Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. , 1987, The Journal of biological chemistry.

[8]  W. Jiskoot,et al.  Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta , 2005, Pharmaceutical Research.

[9]  Y. J. Wang,et al.  Formulation, Characterization, and Stability of Protein Drugs: Case Histories , 2002, Pharmaceutical Biotechnology.

[10]  A. Whitty,et al.  The structure of human interferon-β: implications for activity , 1998, Cellular and Molecular Life Sciences CMLS.

[11]  S. Kimura,et al.  Stability of human interferon-ß1: oligomeric human interferon-ß1 is inactive but is reactivated by monomerization , 1989 .

[12]  C. Wijbrandts,et al.  Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study , 2009 .

[13]  A. Whitty,et al.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). , 1998, Pharmaceutical research.

[14]  A. Hawe,et al.  Stabilization of a hydrophobic recombinant cytokine by human serum albumin. , 2007, Journal of pharmaceutical sciences.

[15]  Alastair Aitken,et al.  Protein Determination by UV Absorption , 1996 .

[16]  David W. Russell,et al.  SDS-Polyacrylamide Gel Electrophoresis of Proteins. , 2006, CSH protocols.

[17]  S Goelz,et al.  The crystal structure of human interferon beta at 2.2-A resolution. , 1997 .

[18]  J. Ralston,et al.  Solution behavior of IFN-beta-1a: an empirical phase diagram based approach. , 2005, Journal of pharmaceutical sciences.

[19]  Jochem Alsenz,et al.  Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.

[20]  G. Antonelli,et al.  Reflections on the immunogenicity of therapeutic proteins. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[21]  H. Eisenberg,et al.  Light scattering , 1976, Nature.

[22]  R. Herndon,et al.  Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis , 2005, Multiple sclerosis.

[23]  W. Jiskoot,et al.  Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. , 2010, Journal of immunological methods.

[24]  Paolo Gallo,et al.  Immunogenicity of interferon beta: differences among products , 2004, Journal of Neurology.

[25]  D. Roth,et al.  Cell Cooperation in the Antibody Response , 2006 .

[26]  M. Barkley,et al.  Toward understanding tryptophan fluorescence in proteins. , 1998, Biochemistry.

[27]  B. Smith,et al.  SDS Polyacrylamide Gel Electrophoresis of Proteins. , 1984 .

[28]  P. Sørensen,et al.  Appearance and disappearance of neutralizing antibodies during interferon-beta therapy , 2005, Neurology.

[29]  P. Soelberg Sørensen Review: Neutralizing antibodies against interferon-beta , 2008 .

[30]  P. Sørensen Neutralizing antibodies against interferon-Beta. , 2008, Therapeutic advances in neurological disorders.

[31]  Patrick Mayeux,et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.

[32]  Luyuan Zhang,et al.  Ultrafast quenching of tryptophan fluorescence in proteins: Interresidue and intrahelical electron transfer , 2008 .

[33]  J. Philo,et al.  A critical review of methods for size characterization of non-particulate protein aggregates. , 2009, Current pharmaceutical biotechnology.

[34]  A. Whitty,et al.  Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity. , 2000, Biochemistry.

[35]  Huub Schellekens,et al.  Immunological mechanism underlying the immune response to recombinant human protein therapeutics. , 2010, Trends in pharmacological sciences.

[36]  M. Hora,et al.  Interferon-β-1b (Betaseron ® ): A Model for Hydrophobic Therapeutic Proteins , 2002 .

[37]  D. Weilguny,et al.  The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model , 1994, Diabetologia.

[38]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[39]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[40]  Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera. , 2008, Journal of immunological methods.

[41]  A. Hawe,et al.  Development of HSA-free formulations for a hydrophobic cytokine with improved stability. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  Huub Schellekens,et al.  Structural Characterization and Immunogenicity in Wild-Type and Immune Tolerant Mice of Degraded Recombinant Human Interferon Alpha2b , 2005, Pharmaceutical Research.

[43]  P. Gallo,et al.  Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. , 2001, European cytokine network.

[44]  Daan J.A. Crommelin,et al.  Methods for structural analysis of protein pharmaceuticals , 2005 .

[45]  J. Faro,et al.  Immune responses to polysaccharides: lessons from humans and mice. , 2008, Vaccine.

[46]  D. Paty,et al.  The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b , 1999, Neurology.

[47]  Huub Schellekens,et al.  Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. , 2006, Journal of Pharmacy and Science.

[48]  P. Sørensen,et al.  Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies? , 2008, Multiple sclerosis.

[49]  T. H. Nguyen,et al.  Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. , 1995, Biochemistry.

[50]  D. Volkin,et al.  Ultraviolet absorption spectroscopy. , 1995, Methods in molecular biology.

[51]  B. Dijkmans,et al.  Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study , 2009, Annals of the rheumatic diseases.

[52]  Adrian Whitty,et al.  Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β) , 1998, Pharmaceutical Research.

[53]  A. Millonig,et al.  High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study , 2009, Multiple sclerosis.

[54]  Amber Haynes Fradkin,et al.  Immunogenicity of aggregates of recombinant human growth hormone in mouse models. , 2009, Journal of pharmaceutical sciences.

[55]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[56]  V. Tomassini,et al.  Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years , 2003, Journal of the Neurological Sciences.